This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
It was very encouraging in the ReNeu trial to see that Gomekli provided deep and durable responses, with a manageable safety profile that enabled patients to stay on therapy. Gomekli demonstrated a manageable safety and tolerability profile. Every treatment approval is hard-won, built on research, persistence, and partnership.
The Companies intend to first evaluate Xyngari with for the topical treatment of primary axillary hyperhidrosis and may explore additional indications through a broader partnership in the future.
The partnership aims to empower football fans everywhere to make proactive decisions about their health, better understand screening guidelines and create a playbook for a healthier future. Novartis is the official first-in-category corporate pharmaceutical partner of the National Football League (NFL).
Whether it’s your first visit to the city or an annual tradition, SHADES at Edge offers a fresh, imaginative way to take in the 360 views of our iconic skyline like never before,” says Francesca Merlino, Chief Commercial Officer at Hudson Yards Experiences, in a news release.
“We are delighted at the launch of Uzpruvo in Europe and to be first-to-market,” adds Robert Wessman, Chief Executive Officer of Alvotech. This launch symbolizes the robustness of our platform, the value of our partnership with STADA, and our collective focus on the importance of biosimilars.”
Eric Hughes, Executive Vice President Global R&D and Chief Medical Officer at Teva, in a news release. This approval marks an important milestone for Teva and Alvotech’s partnership to collaborate on seven biosimilars and expand the availability, access, and uptake of biosimilars in the U.S.”
. “XEOMIN is the first and only FDA-approved neurotoxin for the simultaneous treatment of upper facial lines (forehead lines, frown lines and crow’s feet lines),” says Dr. Samantha Kerr, Chief Scientific Officer at Merz Aesthetics, in a news release.
Tim Raducha-Grace Named Chief Platform Officer at Zerigo Health Tim Raducha-Grace is the new Chief Platform Officer at Zerigo Health, a connected phototherapy platform that couples a handheld Narrow-band ultraviolet B (NB-UVB) light device with a smartphone app and team of care providers to allow patients to treat psoriasis and eczema at home.
Common options include sole proprietorship, partnership, limited liability company (LLC), and corporation. This typically involves obtaining an Employer Identification Number (EIN) from the IRS, registering with your state’s secretary of state office, and obtaining any necessary local business licenses or permits.
Common options include sole proprietorship, partnership, limited liability company (LLC), and corporation. This typically involves obtaining an Employer Identification Number (EIN) from the IRS, registering with your state’s secretary of state office, and obtaining any necessary local business licenses or permits.
It’s pure commonsense ,” Nathan Jones, chief executive officer of Xlear said in a statement. The pharmacology, toxicity, and safety data for NO use in humans has been well-established for decades. Glenmark Pharmaceuticals has signed a partnership with Canadian company SaNOtize Research & Development Corp.,
3 US Facing a Medical Emergency of Misdiagnoses When you visit a doctor, whether you’re at a doctor’s office or hospital, you depend on getting expert care, including a correct diagnosis. But about 11% of the time, 4 medical conditions are misdiagnosed, according to research published in BMJ Quality & Safety. doi: 10.1111/acem.14142.
Relationship impact : honesty and safety measures are key. 20] The American College of Obstetricians and Gynecologists (ACOG) emphasizes the significant morbidity and mortality caused by HPV and strongly recommends HPV vaccination to eligible patients, stressing the benefits and safety of the vaccine.
If you’re as obsessed with high-performance, medical-grade formulations as we are, buckle up because this is a partnership thats about to shake up the skincare game. Every product is clean, non-toxic, and created to work harmoniously with in-office aesthetic treatments. Why Epicutis?
We are thrilled to announce this agreement with Kaken, a dermatology leader with significant reach and expertise in the Japanese market, says Martin Babler, President and Chief Executive Officer of Alumis, in a news release.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content